Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor which is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins for NRAS-mutated solid tumors; RLY-1013, an oral, potent, selective, bifunctional protein degrader of estrogen receptor alpha; RLY-2139, an oral, small molecule, potent, and selective inhibitor of Cyclin-dependent kinases (CDK2) that spares other CDKs. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. Further, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer for the development of RLY-2608. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relay Therapeutics (RLAY) and Sagimet Biosciences, I...

Wall Street Analysts Are Bullish on Top Healthcare Picks

WSW, NY, September 25th, 2026, FinanceWire Three months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-sta...

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX) and Relay Therapeutics (R...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLAY	$17.47	-1.47%	2.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLAY	$17.47	-1.5%	2.98M
3
4
5
6

RLAY

Get Relay Therapeutics, Inc. Data in Excel

Get Relay Therapeutics, Inc. Data in Excel